CONVERGENE

ConverGene is a small molecule discovery company leveraging rational drug design. Our mission is to develop therapeutics with novel mechanisms of action for cancer patients with limited or no treatment options. ConverGene was founded in 2011 after a think tank comprised of six leaders in the fields of genomics and personalized medicine came to the realization that BET proteins could be the key to epigenetic control of MYC. The group decided to focus their deep medicinal chemistry expertise on th... e discovery of novel small molecules that would represent an alternative to the common benzodiazepine core molecules. We have evaluated thousands of molecules and have chosen a few of the most promising as clinical candidates based on improved cancer efficacy and lower side effects in our pre-clinical animal models. All of our initial leaders from 2011 are believers in our core technology and approach. They remain an integral part of ConverGene as Founders, members of our Management Leadership or members of the Scientific Advisory Board.More